145 related articles for article (PubMed ID: 21419444)
1. Overuse of imaging for staging low risk prostate cancer.
Choi WW; Williams SB; Gu X; Lipsitz SR; Nguyen PL; Hu JC
J Urol; 2011 May; 185(5):1645-9. PubMed ID: 21419444
[TBL] [Abstract][Full Text] [Related]
2. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.
Cooperberg MR; Lubeck DP; Grossfeld GD; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):491-5. PubMed ID: 12131295
[TBL] [Abstract][Full Text] [Related]
3. Surveillance testing among survivors of early-stage breast cancer.
Keating NL; Landrum MB; Guadagnoli E; Winer EP; Ayanian JZ
J Clin Oncol; 2007 Mar; 25(9):1074-81. PubMed ID: 17369571
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, diagnosis and treatment of prostate cancer.
Newman J
Radiol Technol; 1996; 68(1):39-64; quiz 65-8. PubMed ID: 8880970
[TBL] [Abstract][Full Text] [Related]
5. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
6. Are staging investigations being overused in patients with low and intermediate risk prostate cancer?
Kim L; Min M; Roos D; Nguyen L; Yeoh E
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):77-81. PubMed ID: 25186469
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
Riley GF; Warren JL; Potosky AL; Klabunde CN; Harlan LC; Osswald MB
Med Care; 2008 Oct; 46(10):1108-15. PubMed ID: 18815533
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment.
Jacobs BL; Skolarus TA; Hollenbeck BK
Urology; 2011 Feb; 77(2):279. PubMed ID: 21295244
[No Abstract] [Full Text] [Related]
9. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
[TBL] [Abstract][Full Text] [Related]
10. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer.
Hendren S; Birkmeyer JD; Yin H; Banerjee M; Sonnenday C; Morris AM
Dis Colon Rectum; 2010 Dec; 53(12):1587-93. PubMed ID: 21178851
[TBL] [Abstract][Full Text] [Related]
11. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.
Stokes ME; Black L; Benedict A; Roehrborn CG; Albertsen P
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521
[TBL] [Abstract][Full Text] [Related]
12. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
[TBL] [Abstract][Full Text] [Related]
13. [Prostatic carcinoma: current status of diagnostic imaging].
Bloch BN; Helbich T; Heinz-Peer G
Wien Med Wochenschr Suppl; 2002; (113):89-91. PubMed ID: 12621851
[TBL] [Abstract][Full Text] [Related]
14. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
Ablin RJ; Sartor O; Bennett CL
Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
[No Abstract] [Full Text] [Related]
15. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma.
Copeland LA; Elshaikh MA; Jackson J; Penner LA; Underwood W
Cancer; 2005 Oct; 104(7):1372-80. PubMed ID: 16118801
[TBL] [Abstract][Full Text] [Related]
16. First-year costs of treating prostate cancer: estimates from SEER-Medicare data.
Roehrborn CG; Albertsen P; Stokes ME; Black L; Benedict A
Prostate Cancer Prostatic Dis; 2009; 12(4):355-60. PubMed ID: 19468284
[TBL] [Abstract][Full Text] [Related]
17. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
18. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
19. [Value of imaging procedures in staging prostate cancer. Is CT out?].
Engelmann U
Urologe A; 1992 Jul; 31(4):195. PubMed ID: 1514195
[No Abstract] [Full Text] [Related]
20. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
